Dendrite Holds Analysts and Investor Meeting; Details New Products & Services; Updates Financial Model; Raises Estimates; Announces 3-for-2 Split.

MORRISTOWN, NJ--(BUSINESS WIRE)--Sept. 15, 1999--

In a meeting yesterday with analysts and investors, Dendrite International, Inc. (NASDAQ/NMS:DRTE) Chairman and CEO John Bailye and fellow executives introduced new product and service offerings and updated the Company's existing business model.

The Company highlighted the Version 2 of its high end product ForcePharma, equipped with web-enabled features and internet integration capabilities, as well as Dendrite's distance learning initiative. Dendrite also announced the launch of PharmaRep.com, a progressive portal/extranet/intranet designed exclusively for pharmaceutical sales forces. The new offerings were presented last week at Dendrite's PharmaQuest global user conference to customers and partners.

After the presentation, Bailye noted, "These new offerings will increase the effectiveness of sales teams from major pharmaceutical companies and will provide their reps with innovative tools not seen previously. The introduction of these new products and services will be of great benefit to sales forces whose primary goals are to increase effectiveness, decrease time away from selling and therefore, boost performance."

At the meeting, the Company indicated that its current 1999 EPS expectation was $0.80 per share. Dendrite also indicated that its 1999 revenue is expected to be approximately $170 million. The Company further estimated revenue growth of 25% and EPS growth of 25%-30% for the calendar year 2000. The Company cautioned that these projected results are annual estimates and may vary on a quarterly basis both in 1999 and beyond.

Executive Vice President and Chief Financial Officer George Robson concluded the meeting, commenting, "Dendrite is truly on solid footing as we look forward to continuing financial improvement and reiterate that growth is the key driver of our financial results."

Finally, Dendrite also announced that its Board of Directors has approved a three-for-two split, to be effected as a stock dividend. Shareholders of record as of the close of business on September 23, 1999 will receive one (1) additional share of the Company's common stock for every two (2) shares held on that date. The payment date for the stock dividend will be on October 7, 1999, and the common stock will begin trading post-split the day after the payment date. No action on the part of shareholders is required.

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1100 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.